Based on data of the ERSPC trial , we predicted the numbers of prostate cancers diagnosed , prostate cancer deaths averted , life-years and quality-adjusted life-years ( QALY ) gained , and cost-effectiveness of 68 screening strategies starting at age 55 years , with a PSA threshold of 3 , using microsimulation modeling .